Akito Yamaguchi

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Operating Times and Bleeding Complications in Percutaneous Nephrolithotomy: A Comparison of Tract Dilation Methods in 5537 Patients in the Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study

Akito Yamaguchi, Andreas Skolarikos, Niels‐Peter Buchholz et al. · Journal of Endourology · 2011 · 235 citations

Medicine, Nephrology, Surgery +15

Prevention of Recurrence With Epirubicin and Lactobacillus Casei After Transurethral Resection of Bladder Cancer

Seiji Naito, Hirofumi Koga, Akito Yamaguchi et al. · The Journal of Urology · 2008 · 147 citations

Medicine, Oncology, Urology +7

Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer

Shiro Hinotsu, Hideyuki Akaza, Seiji Naito et al. · British Journal of Urology · 2010 · 103 citations

Medicine, Oncology, Urology +13